Clinical Trial Update: ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of ADCb (Anlotinib/Docetaxel/Carboplatin) as neoadjuvant therapy for breast cancer is ongoing with status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ADCb (Anlotinib/Docetaxel/Carboplatin)

Snippet

Sponsor: Anqin Zhang | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN